Vericel to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 13th, 2021

Vericel Corporation (NASDAQ:VCEL) announced that Nick Colangelo, President and CEO, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference.

Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL) announced that Nick Colangelo, President and CEO, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference. The event is scheduled for Monday, September 13, 2021, at 4:15 p.m. Eastern Time. Investors can access the webcast through the Investor Relations section of Vericel's website. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing products like MACI® and Epicel®. For further details, visit www.vcel.com.

Argus Session date unavailable

-2.80% session move Open Argus

Details

News Market Reaction – VCEL

The recorded move for VCEL in the trading session of this news was -2.80%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will participate in a virtual fireside chat at the Morgan Stanley 19^th Annual Global Healthcare Conference on Monday, September 13, 2021, at 4:15p.m. Eastern Time.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid^®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2021 Vericel Corporation. All rights reserved.

Investor Contacts:
Eric Burns
ir@vcel.com
+1 734-418-4411

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Nick Colangelo participate in the Morgan Stanley Healthcare Conference?

Nick Colangelo will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 4:15 p.m. Eastern Time.

Where can I watch the Vericel Corporation conference presentation?

The presentation can be accessed via webcast on the Investor Relations section of Vericel's website.

What are the main products offered by Vericel Corporation?

Vericel Corporation offers two main products: MACI® for cartilage defects and Epicel® for severe burn treatment.

What is the stock symbol for Vericel Corporation?

The stock symbol for Vericel Corporation is VCEL.

What is NexoBrid and its significance to Vericel?

NexoBrid is a biological orphan product for the debridement of severe thermal burns, for which Vericel holds an exclusive license in North America.